Navigation Links
Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension

g statements
This press release includes forward-looking statements that involve substantial risks and uncertainties. These forward-looking statements are based on our current expectations and projections about future events. All statements, other than statements of historical facts, regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. The word "may" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations described in these forward-looking statements and you should not place undue reliance on them. There can be no assurance that actual results of our research and development activities and our results of operations will not differ materially from these expectations. Factors that could cause actual results to differ from expectations include, among others: our or our partners' ability to develop safe and efficacious products; our or our partners' ability to achieve positive results in clinical trials; our or our partners' ability to obtain marketing approval and market acceptance for our product candidates; our ability to enter into future collaboration and licensing agreements; the impact of competition and technological change; existing and future regulations affecting our business; changes in governmental oversight of pharmaceutical product development; the future scope of our patent coverage or that of third parties; the effects of any future litigation; general economic and business conditions, both internationally and within our industry, including exchange rate variations; and our future financing plans.


[1] Tekturna® and Rasilez® are Novartis trademarks in the USA and Europe
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
9. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
10. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
11. Bentley Reports Positive Results with Nasulin Intranasal Insulin Spray at the American Diabetes Association Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Speedel Reports Successful SPP635 Phase IIa Trial Hypertension
(Date:9/22/2014)... Sept. 22, 2014 Children,s National Health ... Sept. 29 at 5 p.m. EDT for its ... in response to continued strong interest from inventors.  ... will be awarded to the winning presentations at ... Symposium hosted by Children,s National in October. For ...
(Date:9/22/2014)... 22, 2014 Persistence Market Research ... Market Study on Ophthalmic Devices: Asia ... devices market was valued at USD 29,171.5 million in 2014 ... 6.5% from 2014 to 2020, to reach an estimated ... Browse the full Global Market Study on Ophthalmic Devices:  ...
(Date:9/22/2014)... , Sept. 22, 2014 /CNW/ - T-Bird Pharma ... focused on developing premium quality medical marijuana products, is ... Biomedical Inc. ("Thunderbird"), has signed a definitive lease agreement ... , BC.  The facility has 28,966 square feet ... 14,500 square feet of mezzanine space for a total ...
Breaking Medicine Technology:Calling all medical innovators: Submit your pediatric medical device pitch for Children's National competition by Sept. 29 2Calling all medical innovators: Submit your pediatric medical device pitch for Children's National competition by Sept. 29 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 2Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 4Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 5T-Bird Pharma Inc. to Increase Growing Capacity with Expansion into a 43,500 square feet Second Facility 2T-Bird Pharma Inc. to Increase Growing Capacity with Expansion into a 43,500 square feet Second Facility 3
... CPF Calls on Manufacturer and FDA to Expedite Review of ... The Coalition for Pulmonary Fibrosis (CPF) is calling this a ... a pivotal Phase III clinical trial is completed for Pirfenidone ... way for the first FDA-approved therapy to treat PF - ...
... Intellectual property based on breakthrough research from a ... Montreal Heart Institute Research Centre, Canada.TOULOUSE, France and ... SA (Cerenis), a privately held pharmaceutical company developing ... metabolic diseases, today announced that it has in-licensed ...
Cached Medicine Technology:Positive Data From Lung Study May Lead to First FDA Approved Treatment for Pulmonary Fibrosis 2Positive Data From Lung Study May Lead to First FDA Approved Treatment for Pulmonary Fibrosis 3Cerenis Therapeutics In-Licenses Intellectual Property for New Treatment of Aortic Valve Stenosis 2
(Date:9/22/2014)... whole eye transplant seems futuristic, if not impossible. ... Department of Defense, researchers at University of California, ... make implantation of an entire, functional eye a ... a holy grail for vision restoration," said Jeffrey ... co-recipient with colleagues at University of Pittsburg Medical ...
(Date:9/22/2014)... PA (PRWEB) September 22, 2014 An ... for patients to the problem of side-sleeping. "My lower ... side, so I designed a solution to this problem," ... asleep comfortably than to have your arm 'fall asleep.'" ... on his or her side more comfortably. It avoids ...
(Date:9/22/2014)... West Orange, NJ. September 22, 2014. Kessler researchers ... of a 10-week psychoeducational wellness program in people ... in mood, overall mental health, perceived stress, and ... wellness group for individuals living with MS: Description ... September 3 in the International Journal of ...
(Date:9/22/2014)... MONDAY, Sept. 22, 2014 (HealthDay News) -- Scans ... they learn to read. This finding could potentially ... other reading difficulties early on, preliminary research suggests. ... in children with dyslexia as well as most ... Hoeft, an associate professor of child and adolescent ...
(Date:9/22/2014)... 2014 Pain does not need to rule ... user- and reader-friendly book designed to guide the individual who ... This inspirational book is written to help the reader who ... way to regain a pain-free life — a daily “go-to” ... , Chronic pain has become an epidemic, with over 100 ...
Breaking Medicine News(10 mins):Health News:Looking ahead: Whole eye transplant under development 2Health News:Can Brain Scans Help Predict Young Children's Reading Abilities? 2Health News:Naturopathic Doctor Inspires and Guides Those Who Suffer with Chronic Pain, Pointing the Way Back to Pain-free Living 2
... Francisco's 2002 Gay Pride, San Francisco Department of Public Health ... ,In the above said campaign, a cartoon penis by ... hundreds of homo whores who had gathered there to get ... were not happy with the Ad and scoffed at the ...
... habits, is easily acquired but quite difficult to stop.// All ... or at least have to try out recommended smoking cessation ... the ages of 16 and 24 years do try to ... try out tested methods. ,An article presented in ...
... A US company claimed to have developed a weight reduction ... also could cut the risk of heart disease, diabetes and ... five to 10 percent when taken for a year. ... developed by Californian biopharmaceutical firm Orexigen for 48 weeks lost ...
... apple and plum, now strawberry wine will add variety from ... the Horticulture Produce Marketing Corp's (HPMC) juice and wine processing ... ,The new wine was produced after year-long research by experts ... town Kalpa in Kinnaur district, which produces some of the ...
... Systemic sclerosis (SSc) is a chronic autoimmune disorder ... tissue fibrosis.// More than skin deep, this thickening ... capillaries, the gastrointestinal tract, the lungs, and the ... organ dysfunction, serious illness, and death. Researchers have ...
... better safety for patients in ICU by adhering to ... threatening// catheter-related infections. ICUs can become thoroughly aseptic by ... syringes and catheters. A detailed report was made by ... of the report are published in New England Journal ...
Cached Medicine News:Health News:Tried To Quit Smoking And Failed? Call 1-800-QUIT-NOW 2Health News:New Treatment Offers Hope for Systemic Sclerosis 2Health News:Simple Steps to Safe Guard Patients from Bloodstream Infections in ICU 2
... and high power negative lens delivering magnification ... benefit of this system is ease of ... made possible due to a superior depth ... and individual interpupillary adjustment provides stability for ...
... represents a breakthrough for patients experiencing degenerative ... system gathers bone during decompression, bone bed ... into the implant's chamber produces a local ... the iliac crest. The BAK/C implant is ...
Inside and out, the Achieva is designed to unleash a new era, in which the clinical capabilities of MR will further expand....
Signa Profile is built on the Signa foundation to deliver speed & image quality....
Medicine Products: